A Randomized, Controlled Trial of Daclizumab vs Anti-thymocyte Globulin Induction for Lung Transplantation

Mullen, John C.; Oreopoulos, Antigone; Lien, Dale; Bentley, Michael L.; Modry, Dennis L.; Stewart, Ken G.; Winton, Timothy; Jackson, K.; Doucette, Karen; Preiksaitis, Jutta K.; Halloran, P.

doi:10.1016/j.healun.2007.01.032

Cited by 49 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] Rare but serious complications have been associated with a number of these therapies. [4][5][6][7][8][9][10] The pharmacokinetic half-life of mAbs is typically only 10 to 30 days, but the pharmacodynamic half-life can be significantly longer. For example, the pharmacokinetic half-life of natalizumab in patients with multiple sclerosis (MS) is approximately 11 Ϯ 4 days; however, mean ␣4-integrin saturation levels remain greater than 70% at 4 weeks after infusion.…”

mentioning

confidence: 99%

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Bo¹,

Man²,

Giovannoni³

et al. 2009

Neurology

265

191

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Bo¹,

Man²,

Giovannoni³

et al. 2009

Neurology

265

191

View full text Add to dashboard Cite

show abstract

“…The follow-up study confirmed a reduction in early rejection but showed no difference in survival at 8 years. Mullen et al [43] Single center, prospective, randomized comparison of RATG and daclizumab…”

Section: Ishlt Registrymentioning

confidence: 99%

“…The daclizumab group had a higher incidence of CMV infections. That group also had a higher percentage of CMV mismatches [43]. In the second study, daclizumab was compared with OKT3 and antithymocyte globulin.…”

Section: Efficacymentioning

confidence: 99%

Induction therapy in lung transplantation

Sweet

2013

Transpl Int

View full text Add to dashboard Cite

Strategies for induction in lung transplant recipients typically mirror those used in other solid organ transplant recipients. Polyclonal (Atgam, RATG) and monoclonal (OKT3) T-cell depleting agents, IL-2 Receptor antagonists (basiliximab and daclizumab) have been used most commonly. In spite of evidence from ISHLT registry reports that induction reduces acute rejection and has a small benefit in freedom from bronchiolitis obliterans and long-term survival, other studies have been less convincing in terms of long-term benefit. Future iterations of induction strategy for lung transplant recipients will hopefully utilize tolerogenic approaches currently being tested in renal transplantation.

show abstract

“…[210][211][212] ATG has been used in non-FDA-approved indications for lung transplant rejection and prophylaxis, where the evidence supports a favorable outcome in these clinical situations. [210][211][212] ATG is almost always used in combination with other immunosuppressive agents. [210][211][212] Table 17 summarizes one trial of ATG for renal transplant patients and provides detailed information regarding toxicity.…”

Section: Antithymocyte Globulinmentioning

confidence: 99%

“…[210][211][212] ATG is almost always used in combination with other immunosuppressive agents. [210][211][212] Table 17 summarizes one trial of ATG for renal transplant patients and provides detailed information regarding toxicity. 213 3.3.2.1 Toxicity-ATG (equine) is contraindicated in patients with a personal history of hypersensitivity Table 7 legend for expansion of other abbreviation.…”

Section: Antithymocyte Globulinmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

A Randomized, Controlled Trial of Daclizumab vs Anti-thymocyte Globulin Induction for Lung Transplantation

Cited by 49 publications

References 17 publications

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Induction therapy in lung transplantation

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About